Reena S. Cecchini

Also affiliated with NRG Oncology

Biochemistry, Genetics and Molecular BiologyMathematicsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea”.

Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa160

N/A

0.330DataRank · unranked

8 citations

Daniel J. Schaid, Anthony Batzler, Reena S. Cecchini, Ann H. Partridge, Aaron D. Norman +9 more

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf032

N/A

0.208DataRank · unranked

3 citations

Sungjin Kim, N. Lynn Henry, Ron D. Hays, Vinícius F. Calsavara, Michael Luu +11 more

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps613

N/A

0DataRank · unranked

31 citations

Stewart Anderson, Eleanor Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz +11 more

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

Cancer Prevention Research(2023)10.1158/1940-6207.capr-23-0216

N/A

0DataRank · unranked

4 citations

N. Lynn Henry, Ron D. Hays, Sungjin Kim, Michael Luu, Márcio A. Diniz +7 more

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps623

N/A

0DataRank · unranked

6 citations

Reena S. Cecchini, Eleanor Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz +12 more

Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials

JNCI Monographs(2025)10.1093/jncimonographs/lgae047

N/A

0DataRank · unranked

7 citations

Pedro A. Torres‐Saavedra, Eva Culakova, Heather Gunn, Minji K. Lee, Fenghai Duan +5 more

Analyses of adverse events and patient‐reported outcomes with the toxicity index in cancer clinical trials

Cancer(2025)10.1002/cncr.70086

N/A

0DataRank · unranked

1 citations

N. Lynn Henry, Hanna Bandos, Vinícius F. Calsavara, Reena S. Cecchini, Márcio A. Diniz +8 more

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30

npj Breast Cancer(2022)10.1038/s41523-022-00489-9

N/A

0DataRank · unranked

9 citations

Sungjin Kim, Ron D. Hays, Márcio A. Diniz, Mourad Tighiouart, Gillian Gresham +6 more